 
            
                           ICICI Securities research report on DOMS Industries
Takeaways: (1) DOMS’ strong investments in writing instruments and scholastic art material in FY24 have yielded strong segmental growth YoY. We highlight DOMS reporting strong revenue growth in segments that had strong capacity expansion in past. Strong growth in both these segments underlines the same. (2) EBITDA margin scaled to 19.4% (+302bps YoY) led by operative leverage. (3) Unlike past acquisitions, largely revolving around stationery and art materials, DOMS acquired controlling stake in Uniclan Healthcare – manufacturer of baby care/hygiene products. This may aid in broadening its total addressable market. (4) Core pencil segment capacity is set to increase to ~8mn/day, from current 5.7mn/day by FY25-end. We expect this to drive incremental growth for DOMS in FY26. We expect capacity addition to primarily drive strong growth in FY25/FY26. Maintain BUY.
Outlook
We model DOMS to report revenue and PAT CAGRs of 30.8% and 33.4%, respectively, over FY24-26E. We also model RoE to be >20% over FY24-26E. We maintain BUY on DOMS with a DCF-based revised target price of INR 2,650 (earlier INR 2,280; implied P/E of 60x FY26E).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.